Localising Global Molecular Innovation for Malaysia
MyRNA Diagnostics Sdn. Bhd. is a Malaysia-based molecular diagnostics company established to build Malaysia’s early cancer detection hub.
Cancer in Malaysia is often detected too late
MyRNA Diagnostics Sdn. Bhd. is a Malaysia-based molecular diagnostics company established to build the nation’s early cancer detection hub. Formed as a strategic joint venture between Xeraya Opportunities Fund and MiRXES, MyRNA serves as the Malaysian vehicle for localising miRNA-based precision diagnostics and scaling advanced molecular screening across the country and, in time, the broader ASEAN region.
MyRNA was created in response to a structural healthcare challenge. In Malaysia, a significant proportion of cancers are detected at late stages, when treatment becomes more intensive, outcomes are poorer, and healthcare costs escalate. Despite national health initiatives and increased awareness, screening uptake and early detection rates remain insufficient across several high-burden cancers. There exists a critical gap between risk and diagnosis — a gap that demands earlier, accessible, and clinically actionable solutions.
MyRNA’s role is to address this gap by introducing validated, blood-based molecular screening tools into structured clinical pathways. Rather than replacing existing standards of care, MyRNA enhances them by positioning miRNA-based tests as an earlier triage layer. Through this approach, individuals at higher risk can be identified sooner and referred appropriately for confirmatory procedures such as gastroscopy or imaging. At the same time, unnecessary procedures for low-risk individuals may be reduced, improving system efficiency and patient experience
Establish the Foundation
We formed MyRNA as Malaysia’s strategic joint venture platform to localise globally validated miRNA diagnostics. This phase focused on regulatory groundwork, partnership building, and commissioning an ISO 15189-accredited molecular laboratory in Cyberjaya to anchor national operations.
Launch & Localise Early Detection
We introduced blood-based miRNA screening solutions into structured clinical pathways, beginning with gastric and lung cancer risk stratification. Through phased site activation across hospitals and screening centres, we transitioned from cross-border testing to fully localised laboratory analytics with defined turnaround time governance.
Scale the National Platform
We are scaling toward a nationwide early detection ecosystem, activating 25–30 clinical sites and embedding “Blood-First Triage” into Malaysia’s healthcare pathways. Our long-term ambition is to position Malaysia as an ASEAN launchpad for multi-omics precision diagnostics and sustainable early cancer detection infrastructure.
Driven by Purpose, Guided by Values
Our Vision
MyRNA’s vision is to democratise early disease detection — when it is most treatable. We believe that timely access to accurate molecular insights can fundamentally shift clinical outcomes and reduce the long-term burden of cancer on individuals, families, and the healthcare system.
Our Mission
Our mission is to localise miRNA-based diagnostics and scale multi-omic solutions by building cost-efficient operations, advancing region-specific research and validation, and delivering integrated service platforms for healthcare professionals and patients. Through this strategy, MyRNA aims to position Malaysia as a regional launchpad for best-in-class molecular diagnostics over the coming decade.
Our Strategic Direction
MyRNA’s immediate focus is on gastric and lung cancer risk stratification, leveraging flagship miRNA assays designed to function within a “blood-first triage” framework. Over time, the platform is intended to expand toward broader multi-omic capabilities and additional cancer indications, strengthening Malaysia’s role in the precision medicine value chain.
The company’s growth model is deliberately phased and disciplined. Laboratory commissioning, regulatory alignment, site activation, and channel expansion are sequenced to ensure operational readiness and sustainable scale. This structured approach enables MyRNA to build clinical trust, generate real-world evidence, and establish durable partnerships with healthcare institutions and policymakers.
Governance and Commitment
As a joint venture entity, MyRNA operates under a governance framework that reflects its strategic shareholders and long-term objectives. The company is committed to regulatory compliance, quality management, and transparent reporting. Accreditation pathways, including ISO 15189 alignment, are integral to ensuring that laboratory operations meet internationally recognised standards. Data protection and ethical handling of patient information remain fundamental priorities in all aspects of service delivery.
Beyond commercial performance, MyRNA measures success through impact. Earlier detection can significantly improve survival probabilities and reduce the economic burden of late-stage treatment. By embedding precision diagnostics into Malaysia’s healthcare pathways, MyRNA contributes directly to national goals focused on prevention, equitable access, and system sustainability.
What Drives Us
Our core values guide everything we do and define who we are as an organization.